Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by QualityTeston Sep 28, 2020 9:10am
215 Views
Post# 31628121

RE:RE:Discussions Involve Multiple Partners in Varying Formats

RE:RE:Discussions Involve Multiple Partners in Varying FormatsI don't recall seeing any data tha differentiated SGLTs either so afaik none have been shown to work significantly better than others. 

I've seen you mention $8/share before from Agoracom. I think that was just one poster's guess as to where we would be at in August. Nothing scientific or from a company source.

I think upfront payment will be >$100m as well, but trying not to get myself too excited. Someone on Agora a couple weeks ago listed some prior pharma partnership deals and the upfront payments were generally substantial. I can't find that post now though to share, unfortunately. 
<< Previous
Bullboard Posts
Next >>